Company Active LTD

Company profile

Ryedale Group Limited

Home - Ryedale Printing

Ryedale Group Limited is a UK company with status active founded in 2004 based in Yorkshire and the Humber.

CRN
05128618
Founded
2004
Age
22

Overview

Legal name
RYEDALE GROUP LIMITED
Region
Yorkshire and the Humber
Registered address
RYEDALE GROUP KIRKDALE ROAD
KIRKBYMOORSIDE
YORK
ENGLAND
YO62 6YB
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Ryedale Group Limited
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

9 events
28 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2026

Accounts due

Accounts Due

Next accounts due date

26 May
2026

Notification Of A Person With Significant Control

Persons-with-significant-control

PSC01 | Transaction MzUyMzY5NTQ2NGFkaXF6a2N4

Published 26 May 2026 14:40

26 May
2026

Notification Of A Person With Significant Control

Persons-with-significant-control

PSC01 | Transaction MzUyMzY5NDg5NGFkaXF6a2N4

Published 26 May 2026 14:37

26 May
2026

Change To A Person With Significant Control

Persons-with-significant-control

PSC04 | Transaction MzUyMzY5NDIyMmFkaXF6a2N4

Published 26 May 2026 14:33

26 May
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzUyMzY4NTAxMGFkaXF6a2N4

Published 26 May 2026 13:37

14 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2024

Accounts filed

Accounts

Last accounts made up date

14 May
2004

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2011
Funded years
2011
Age at first award
7 years

Projects

2011 Collaborative R&D

PROCID - Biosensor platform for rapid point-of-collection diagnosis of infectious diseases

1 Dec 2011 to 30 Nov 2013

Awarded
£47,834
Total cost £120,631

The PROCID programme is designed to prove the cost effective use of printed copper in low cost antibody based biosensors for disease detection, initially targeting the STD’s Chlamydia and Gonorrhea. This will provide a step change in ease of detection to combat and overcome the spread of infections. Key objectives include: development of low-cost biosenso...

Product types

Collaborative R&D